ReviewBreast cancer research : BCR2012
Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality.
Review in Breast cancer research : BCR, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The relationship between exposure to particulate matter and breast cancer incidence and mortality: A meta-analysis.Medicine · 2019Pooled it
- Aspirin intake and breast cancer survival - a nation-wide study using prospectively recorded data in Sweden.BMC cancer · 2014Trial
- Innovative, rapid, high-throughput method for drug repurposing in a pandemic-A case study of SARS-CoV-2 and COVID-19.Frontiers in pharmacology · 2023Article
- Cholesterol lowering drug use and breast cancer survival: the Multiethnic Cohort Study.Breast cancer research and treatment · 2021Article
- Review
- Independent and joint cross-sectional associations of statin and metformin use with mammographic breast density.Breast cancer research : BCR · 2020Article
- Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin.Acta oncologica (Stockholm, Sweden) · 2020Article
- Article
- Particulate Matter and Traffic-Related Exposures in Relation to Breast Cancer Survival.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019Article
- No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study.Breast cancer research : BCR · 2018Article
- Disease or not, aging is easily treatable.Aging · 2018Article
- Pre-diagnostic statin use, lymph node status and mortality in women with stages I-III breast cancer.British journal of cancer · 2017Article
- Synergistic drug combinations from electronic health records and gene expression.Journal of the American Medical Informatics Association : JAMIA · 2017Article
- De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I-III breast cancer.British journal of cancer · 2016Article
- Low-dose Aspirin, Nonsteroidal Anti-inflammatory Drugs, Selective COX-2 Inhibitors and Breast Cancer Recurrence.Epidemiology (Cambridge, Mass.) · 2016Article
- Aspirin Breaks the Crosstalk between 3T3-L1 Adipocytes and 4T1 Breast Cancer Cells by Regulating Cytokine Production.PloS one · 2016Article
- Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.World journal of gastrointestinal pathophysiology · 2015Article
- Diabetes and other comorbidities in breast cancer survival by race/ethnicity: the California Breast Cancer Survivorship Consortium (CBCSC).Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2015Article
- Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.International journal of cancer · 2014Article
- Statins and breast cancer prognosis: evidence and opportunities.The Lancet. Oncology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many medications have been developed for one purpose but then are found to have other clinical activities. There is tremendous interest in whether non-cancer medications may potentially have effects on breast cancer survival. In this review article, we have presented and evaluated the evidence for several commonly used over-the-counter and prescription medications - including aspirin (and other non-steroidal anti-inflammatory drugs), beta-blockers, angiotensin-converting enzyme inhibitors, statins, digoxin, and metformin - that have been evaluated among breast cancer survivors in prospective studies. Substantial scientific evidence supports the hypothesis that some of these common and relatively safe drugs may reduce breast cancer mortality among those with the disease by an amount that rivals the mortality reduction gained by currently used therapies. In particular, the evidence is strongest for aspirin (approximately 50% reduction), statins (approximately 25% reduction), and metformin (approximately 50% reduction). As these drugs are generic and inexpensive, there is little incentive for the pharmaceutical industry to fund the randomized trials that would show their effectiveness definitively. We advocate that confirmation of these findings in randomized trials be considered a high research priority, as the potential impact on human lives saved could be immense.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.